Dallas, TX 的 卵巢癌 臨床試驗
28 項針對 卵巢癌 的研究正在 Dallas（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
招募中2/3 期
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- UT Southwest Simmons Cancer Center, Dallas
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- UT Southwestern, Dallas
Study of AVZO-021 in Patients With Advanced Solid Tumors
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Dallas
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
招募中3 期
- UT Southwestern Medical Center, Dallas
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
招募中1 期
- Texas Oncology - DFW (Sammons CC), Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
招募中觀察性研究
- UT Southwestern Medical Center, Dallas
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
招募中2 期
- UT Southwestern Medical Center, Dallas
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
招募中1 期
- SCRI - Mary Crowley Cancer Research, Dallas
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Dallas
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
招募中3 期
- Parkland Memorial Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
招募中1/2 期
- Texas Oncology, P.A., Dallas
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- Mary Crowley Cancer Research, Dallas
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
招募中1/2 期
- Mary Crowley Cancer Research, Dallas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
招募中2 期
- Baylor Scott & White Research Institute, Dallas
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
招募中2 期
- Texas Oncology - DFW, Dallas
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
招募中1/2 期
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
- University of Texas Southwestern, Dallas
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- Texas Oncology, P.A., Dallas
Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
招募中
- UT Southwestern Parkland Health and Hospital System, Dallas
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
招募中1/2 期
- Next Oncology, Dallas
- UTSW Medical Center, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
招募中1 期
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
招募中1 期
- Dren Investigational Site, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Dallas
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
招募中1/2 期
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
招募中1 期
- Mary Crowley Cancer Research, Dallas
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
招募中1 期
- NEXT Oncology, Dallas, Dallas
其他城市的 卵巢癌 試驗
- Houston, TX89 項研究
- New York City, NY69 項研究
- Boston, MA61 項研究
- Los Angeles, CA50 項研究
- Nashville, TN49 項研究
- Arlington, VA46 項研究
- Philadelphia, PA44 項研究
- Columbus, OH39 項研究
- St. Louis, MO38 項研究
- Chicago, IL36 項研究
- San Antonio, TX31 項研究
- Cleveland, OH30 項研究
Dallas 的其他研究
- 乳癌55 項研究
- 非小細胞肺癌52 項研究
- 轉移性癌症42 項研究
- 心臟衰竭42 項研究
- 癌症（所有類型）37 項研究
- 前列腺癌36 項研究
- 大腸直腸癌33 項研究
- 肥胖症30 項研究
- 肺癌27 項研究
- 膀胱癌27 項研究
- 子宮內膜癌24 項研究
- 腎臟癌（腎細胞癌）23 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。